(Q38194895)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

review article

1 reference

title

The BAFF/APRIL system in SLE pathogenesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Eric F. Morand

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Pascal Schneider

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Fabienne Mackay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Fabien B Vincent

1

1 reference

30 August 2017

Eric F Morand

2

1 reference

30 August 2017

Pascal Schneider

3

1 reference

30 August 2017

Fabienne Mackay

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

11 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

365-373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.33

10 March 2020

exact match

0 references

cites work

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF mediates survival of peripheral immature B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

New ELISA for B cell-activating factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

31 March 2020

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Selective APRIL blockade delays systemic lupus erythematosus in mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Novel evidence-based systemic lupus erythematosus responder index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Clinical associations of serum interleukin-17 in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

The geoepidemiology of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1980 to 1992

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Effects of APRIL (TNFSF13) polymorphisms and splicing isoforms on the secretion of soluble APRIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

BAFF and MyD88 signals promote a lupuslike disease independent of T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Serum interferon levels in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Potential role of IFNα in adult lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

The crystal structure of a proliferation-inducing ligand, APRIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

hsBAFF enhances activity of NK cells by regulation of CD4(+) T lymphocyte function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.33

A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease

31 March 2020

1 reference

12 December 2020

B-cell activating factor promoter polymorphisms in egyptian patients with systemic lupus erythematosus

1 reference

12 December 2020

Serum levels of interferons in patients with systemic lupus erythematosus

1 reference

12 December 2020

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

12 December 2020

Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614588%20AND%20SRC:MED&resulttype=core&format=json